IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1–15. (Canceled)

16. (Withdrawn) A therapeutic combination comprising (a) a compound having the formula



wherein

n is a number from 1 to 5;

R2 is OA, and R3 and R4 are each independently selected from H and OA, where A is H, C1–3 alkyl or a group



where R6 and R7 are each independently alkyl or aryl;

R5 is C1–3 alkyl;

R1 is a group



where X is S, O or NH;

or a racemate or pure (R)- or (S)-enantiomer thereof, a physiologically acceptable salt thereof; and (b) one or more additional active ingredients comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents.

17. (Currently amended) A method for treating depression in a mammal, comprising administering to the mammal a therapeutically effective amount of **5,6,7,8-tetrahydro-**

6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol ~~**a compound having the formula**~~



~~**wherein**~~

~~**n is a number from 1 to 5;**~~

~~**R2 is OA, and R3 and R4 are each independently selected from H and OA, where**~~

~~**A is H, C_{1-3} alkyl or a group**~~



~~**or**~~

~~**where R6 and R7 are each independently alkyl or aryl;**~~

~~**R5 is C_{1-3} alkyl;**~~

~~**R1 is a group**~~



~~**or**~~

~~**where X is S, O or NH;**~~

~~**or a racemate or pure (R)- or (S)-enantiomer thereof,**~~ or a physiologically acceptable salt thereof.

18–23. (Canceled)

24. (Previously presented) The method of Claim 17, wherein the mammal is human.

25. (Previously presented) The method of Claim 24, wherein the depression is an endogenous depression.

26. (Previously presented) The method of Claim 25, wherein the endogenous depression is a unipolar depression (major depression) or a depressive phase of a manic-depressive disorder.

27. (Previously presented) The method of Claim 38, wherein the somatogenic depression is an organic depression not associated with Parkinson's disease.

28. (Previously presented) The method of Claim 38, wherein the somatogenic depression is an organic depression associated with Parkinson's disease.

29. (Previously presented) The method of Claim 28, wherein co-medication with another antidepressant is absent.

30. (Currently amended) The method of Claim 24, wherein the ~~compound or racemate or enantiomer thereof~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered parenterally, transdermally or mucosally.

31. (Currently amended) The method of Claim 24, wherein the ~~compound or racemate or enantiomer thereof~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is formulated as an ointment, paste, spray, film, plaster or iontophoretic device for transdermal administration.

32. (Currently amended) The method of Claim 24, wherein the ~~active ingredient~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol or salt thereof** is administered transdermally ~~via~~ **as an active ingredient of** a plaster having the active ingredient **dispersed** in a matrix comprising an adhesive polymer.

33. (Currently amended) The method of Claim 24, wherein the ~~active ingredient~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol or salt thereof** is administered transdermally and wherein a substantially constant plasma level of ~~the active ingredient~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** is established.

34. (Currently amended) The method of Claim 24, wherein the ~~compound or racemate or enantiomer thereof~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered in a dose of 0.5 to about 50 mg per day.

35. (Previously presented) The method of Claim 17, further comprising administering to the mammal one or more antidepressants.

36. (Withdrawn) The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more antidepressants comprising one or more selective serotonin reuptake inhibitors, mixed serotonin and noradrenaline reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor and/or serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis.

37. (Currently amended) The method of Claim **[[23]]** **17**, wherein at least 90 mol % of the compound is in the form of the ~~**S-enantiomer**~~ **(S)-enantiomer**.

38. (Previously presented) The method of Claim 24, wherein the depression is a somatogenic depression.

39. (Previously presented) The method of Claim 27, wherein the organic depression is associated with brain tumor, migraine, epilepsy, brain paralysis, arteriosclerosis of the brain, brain trauma, meningitis, stroke, Parkinson Plus syndrome, dementia and/or cerebrovascular disease.

40. (Previously presented) The method of Claim 27, wherein the depression is associated with Alzheimer's disease.

41. (Previously presented) The method of Claim 38, wherein the somatogenic depression is a symptomatic depression.

42. (Previously presented) The method of Claim 41, wherein the symptomatic depression is associated with circulatory illness, hypothyroidism, hormone disorder, infectious disease, cancer and/or liver disease.

43. (Previously presented) The method of Claim 38, wherein the somatogenic depression is a pharmacogenic depression.

44. (Previously presented) The method of Claim 43, wherein the pharmacogenic depression is associated with alcohol, medication and/or drug misuse.

45. (Previously presented) The method of Claim 24, wherein the depression is a psychogenic depression.

46. (Previously presented) The method of Claim 45, wherein the psychogenic depression comprises at least one of exhaustion depression, neurotic depression and reactive depression as a result of current conflicts or events.

47. (Previously presented) The method of Claim 24, wherein the depression is a specific life situation depression, comprising at least one of postpartum depression, old-age depression, childhood depression, seasonal depression and pubertal depression.

48. (Previously presented) The method of Claim 17, wherein the depression is associated with an affective disorder.

49. (Previously presented) The method of Claim 48, wherein the affective disorder comprises a recurrent depressive disorder and/or depressive phases in bipolar affective disorder.

50. (Previously presented) The method of Claim 17, wherein the depression manifests as depressive symptoms accompanying at least one anxiety disorder, adjustment disorder and/or organic brain disease.

51. (Currently amended) The method of Claim 24, wherein the ~~**compound or racemate or enantiomer thereof**~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered in a dose of 0.1 to about 50 mg per day.

52. (Currently amended) The method of Claim 24, wherein the ~~**compound or racemate or enantiomer thereof**~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered in a dose of 0.2 to 40 mg per day.

53. (Currently amended) The method of Claim 24, wherein the ~~**compound or racemate or enantiomer thereof**~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered in a dose of 0.4 to 20 mg per day.

54. (Currently amended) The method of Claim 24, wherein the ~~**compound or racemate or enantiomer thereof**~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-**

naphthol or salt thereof is administered in a dose of 0.5 to 10 mg per day.

55. (Currently amended) The method of Claim 24, wherein the ~~**compound or racemate or enantiomer thereof**~~ **5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof is administered in a dose of 0.5 to 5 mg per day.

56. (Previously presented) The method of Claim 35, wherein the one or more antidepressants comprise one or more serotonin reuptake inhibitors, mixed serotonin and noradrenalin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase inhibitors, alpha2 receptor modulators, serotonin receptor modulators, adenosine antagonists, sigma-opioid receptor ligands, NK antagonists, melatonin antagonists and/or modulators of the hypothalamus-hypophysis-adrenal axis.

57. (Currently amended) The method of Claim **[[56]]** **35**, wherein the one or more antidepressants comprise at least one of sertraline, citalopram, paroxetine, fluoxetine, venlaxafine, milnacipram, ~~**mirtazapine,**~~ amitryptiline, imipramine, reboxetine, tranylcypramine, clorgyline, mirtazapine and/or nefazodone.

58. (Previously presented) The method of Claim 17, further comprising administering to the mammal one or more antipsychotics.

59. (Previously presented) The method of Claim 58, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

60. (Previously presented) The method of Claim 17, further comprising administering to the mammal one or more sedatives.

61. (Previously presented) The method of Claim 60, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan

and/or zaleplon.

62. (Previously presented) The method of Claim 17, further comprising administering to the mammal one or more anxiolytics.

63. (Previously presented) The method of Claim 62, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

64. (Previously presented) The method of Claim 17, further comprising administering to the mammal one or more anti-migraine agents.

65. (Previously presented) The method of Claim 64, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol.

66. (Currently amended) The method of Claim 17, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein ~~**said compound or racemate or enantiomer thereof**~~ **the 5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** or salt thereof and the at least one additional active ingredient are provided in separate dosage forms for administration by the same or different routes at the same or different times.

67. (Currently amended) The method of Claim 17, further comprising administering to the mammal at least one additional active ingredient comprising one or more antidepressants, antipsychotics, sedatives, anxiolytics and/or anti-migraine agents, wherein ~~**said compound**~~ **the 5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol** and the at least one additional active ingredient are administered in a single dosage form.

68. (Withdrawn) The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more antipsychotics.

69. (Withdrawn) The combination of Claim 68, wherein the one or more antipsychotics comprise at least one of promethazine, fluphenazine, perphenazine, levomepromazine, thioridazine, perazine, promazine, chlorprothixene, zuclopenthixol, prothipendyl, flupentixol, zotepine, benperidol, pipamperon, melperon, haloperidol, bromperidol, sulpiride, clozapine, pimozide, risperidone, quetiapine, amisulpride and/or olanzapine.

70. (Withdrawn) The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more sedatives.

71. (Withdrawn) The combination of Claim 70, wherein the one or more sedatives comprise at least one of diphenhydramine, doxylamine succinate, nitrazepam, midazolam, lormetazepam, flunitrazepam, flurazepam, oxazepam, bromazepam, triazolam, brotizolam, temazepam, chloral hydrate, zopiclone, zolpidem, tryptophan and/or zaleplon.

72. (Withdrawn) The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more anxiolytics.

73. (Withdrawn) The combination of Claim 72, wherein the one or more anxiolytics comprise at least one of fluspirilene, thioridazine, oxazepam, alprazolam, bromazepam, lorazepam, prazepam, diazepam, clobazam, medazepam, chlordiazepoxide, dipotassium chlorazepate, nordazepam, meprobamate, buspirone, kavain and/or hydroxyzine.

74. (Withdrawn) The combination of Claim 16, wherein the one or more additional active ingredients comprise one or more anti-migraine agents.

75. (Withdrawn) The combination of Claim 74, wherein the one or more anti-migraine agents comprise at least one of almotriptan, zolmitriptan, acetylsalicylic acid, ergotamine, dihydroergotamine, methysergide, iprazochrome, ibuprofen, sumatriptan, rizatriptan, naratriptan and/or paracetamol.

76. (Withdrawn) The combination of Claim 16, wherein said compound, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in separate dosage forms adapted for administration by the same or different routes at the same or different times.

77. (Withdrawn) The combination of Claim 16, wherein said compound, or racemate or enantiomer thereof or salt thereof, and the one or more additional active ingredients are present in a single dosage form.

78. (New) The method of Claim 17, wherein the 5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthol or salt thereof is a racemate or a pure (R)- or (S)-enantiomer.